Even they admit the study is flawed: “Another caveat is that many people in our study broke blind and they figured out what condition they were assigned to,” v

Even they admit the study is flawed: “Another caveat is that many people in our study broke blind and they figured out what condition they were assigned to,” van Elk added. “This is a more generic problem for this type of research: the effects of psychedelics are so obvious — even at lower doses — that it is difficult to prevent people from figuring out what condition they are assigned to. If people subsequently figure out that they are in the active/experimental condition (e.g., based on subtle side-effects), this in turn can contribute again to the placebo response.” It's not hard to figure out you've taken actual mushrooms. Also The study included a carefully screened sample of 75 participants who attended a microdosing workshop. They are apparently testing people with normal levels of depression and anxiety, people who are functional enough to attend a microdosing workshop. Perhaps normal people won't benefit from microdosing, but I don't think this study is conclusive. I took from the title they were attempting to treat people with clinical or major depression and anxiety where the actual therapeutic research interest lies., but that's not the case. I'm not advocating microdosing, but it's interesting.